Edition:
United Kingdom

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

54.07EUR
18 Jun 2019
Change (% chg)

-- (--)
Prev Close
€54.07
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,507,331
52-wk High
€99.90
52-wk Low
€52.02

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and... (more)

Overall

Beta: 1.10
Market Cap(Mil.): €48,986.95
Shares Outstanding(Mil.): 932.55
Dividend: 2.80
Yield (%): 5.33

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 49.10 31.89 36.81
EPS (TTM): 1.07 -- --
ROI: 1.19 12.41 12.05
ROE: 2.30 13.73 16.96

Bayer asks trial judge to reverse $2 billion Roundup jury verdict

Bayer AG has asked a California judge to overrule a $2 billion verdict by jurors who found the company's glyphosate-based Roundup weed killer responsible for a couple's cancer, arguing the jury decision was not supported by evidence.

18 Jun 2019

Bayer asks trial judge to reverse $2 billion Roundup jury verdict

June 18 Bayer AG has asked a California judge to overrule a $2 billion verdict by jurors who found the company's glyphosate-based Roundup weed killer responsible for a couple's cancer, arguing the jury decision was not supported by evidence.

18 Jun 2019

Roche wins Japan approval for personalised cancer drug Rozlytrek

ZURICH Swiss drugmaker Roche's push into personalised cancer medicines hit a milestone on Tuesday with Japanese approval of a new drug, Rozlytrek, that targets patients who must be identified via genetic profiling.

18 Jun 2019

Roche wins Japan approval for personalized cancer drug Rozlytrek

ZURICH Swiss drugmaker Roche's push into personalized cancer medicines hit a milestone on Tuesday with Japanese approval of a new drug, Rozlytrek, that targets patients who must be identified via genetic profiling.

18 Jun 2019

UPDATE 1-Roche wins Japan approval for personalised cancer drug Rozlytrek

ZURICH, June 18 Swiss drugmaker Roche's push into personalised cancer medicines hit a milestone on Tuesday with Japanese approval of a new drug, Rozlytrek, that targets patients who must be identified via genetic profiling.

18 Jun 2019

Bayer to invest $5.6 billion in weedkiller research to help reputation

FRANKFURT Germany's Bayer sought to repair its reputation on Friday after damage caused by U.S. litigation over claims its glyphosate pesticide causes cancer, saying it would invest 5 billion euros ($5.6 billion) in weedkiller research.

14 Jun 2019

UPDATE 2-Bayer to invest $5.6 bln in weedkiller research to help reputation

* CEO seeks to improve image amid U.S. glyphosate lawsuits (Adds details on investment, developing countries, lobbyist)

14 Jun 2019

Bayer says to invest five billion euros in new weed killers

BERLIN Bayer said it would invest 5 billion euros (£4.5 billion) in developing new weedkillers and reducing its environmental impact by 30% by 2030, as it seeks to address the fallout from U.S. class-action litigation over glyphosate.

14 Jun 2019

Bayer says to invest 5 bln euros in new weed killers

BERLIN, June 14 Bayer said it would invest 5 billion euros ($5.6 billion) in developing new weedkillers and reducing its environmental impact by 30% by 2030, as it seeks to address the fallout from U.S. class-action litigation over glyphosate.

14 Jun 2019

Bayer teams up with biotech firm Arvinas in deal worth up to $750 million

FRANKFURT German drugmaker Bayer has signed an alliance with Arvinas Inc to gain access to the U.S. biotech firm's experimental protein drugs and crop protection technology in a deal worth up to $750 million.

04 Jun 2019

Earnings vs. Estimates